Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
abducens nerve paralysis
acetylcholine receptor antibody
acoustic nerve
advances in neurology
adverse drug reaction
afebrile
agitation
anti GQ1b IgG antibody
antiviral agents
aphasia
areflexia
arteritides
arteritis, temporal
arteritis, temporal, recurrent
arthralgia
ataxia, sensory
atezolizumab
atypical
autoantibodies
autoimmune disease
autonomic dysfunction
B cell lymphoma
brain biopsy
Broca's aphasia
burning paresthesia
cancer associated myopathy
carcinoma
carcinoma of lung
cardiotoxicity
CAT scan, emission, abnormal
cauda equina
cauda equina, enhancement
cauda equina, lesion of
CD19-directed chimeric antigen receptor T-cell therapy
cerebellitis
cerebellitis, autoimmune
cerebral arteries
cerebrovascular accident
chemotherapy, CNS treatment and complications with
chorea
coinfection
complications
confusion
confusional state, acute
cranial nerve palsies
cranial neuropathy
cranial neuropathy, multiple
creatine phosphokinase(CPK)elevated
cytokine release syndrome
dabrafenib
demyelinating disease
dentate nuclei
dentate nuclei, lesion of
diabetes insipidus
differential diagnosis
diplopia
disorientation
dropped head syndrome
drug abuse
drug induced neurologic disorders
duvalumab
dyspnea
efficacy
electroencephalogram, abnormalities of
electromyogram
encephalitis
encephalitis, autoimmune
encephalitis, viral
encephalopathy
encephalopathy, acute
episodic disorders
extralimbic encephalitis
face, numbness of
facial nerve palsy
fever
Fisher's syndrome
gammaglobulin therapy, intravenous
ganglionitis
glutamic acid decarboxylase, antibody
granulomatous hypophysitis
Guillain Barre syndrome
hallucination
hallucination, auditory
hallucination, visual
headache
hemiparesis
hemiplegia, progressive
hippocampal atrophy
hippocampus, hyperintense
Hodgkin's disease
human herpesvirus 6
hyperactivity
hypercalcemia
iatrogenic neurologic disorders
idiopathic
immune checkpoint inhibitors
immune effector cell-associated neurotoxicity syndrome
immune-related adverse events
immunologic disease
immunomodulation
immunosuppression
immunosuppressive agents
immunotherapy
incidence
internal carotid artery
ipilimumab
JC virus
leukopenia
levamisole
limb-girdle weakness
limbic encephalitis
limbic system
lymph node biopsy
lymphadenopathy
lymphoma
lymphoma, systemic
melanoma, malignant
memory, impairment of
meningismus
meningitis
meningitis, drug induced
meningoencephalitis
mental status, abnormal
mesial temporal lobe
middle cerebral artery
misdiagnosis
monoclonal antibodies
mortality
MRI, abnormal
MRI, angiography
MRI, contrast enhanced
MRI, diffusion weighted
MRI, FLAIR
MRI, optic nerve
multiple organ failure
multiple sclerosis
muscle biopsy
muscle pain
muscle weakness
muscle weakness, proximal
myasthenia gravis
myasthenia gravis, drug induced
myasthenia gravis, unmasked
myocarditis
myopathy
myopathy, inflammatory
myopathy, necrotizing
myopathy, necrotizing, immune-mediated
myositis
nausea and vomiting
neck weakness
neoplasm, metastatic
neoplasm, metastatic to CNS
neoplasm, metastatic to CNS-treatment of
neurologic complications of, systemic cancer
neurologic complications of, systemic disease
neurologic disease
neurologic disease, diagnoses of
neurologic disease, multiple
neuromuscular junction
neuromuscular junction, abnormality of
neuronopathy, sensory
neuroophthalmology
neuropathy
neuropathy, iatrogenic
neuropathy, medication induced
neuropathy, sensory
neurotoxic
nivolumab
ocular motility, disorders of
ophthalmoplegia
opportunistic infection
opportunistic infection, CNS
optic disc edema
optic nerve, enhancement
optic neuritis
optic neuropathy
orthostatic hypotension
paraneoplastic ganglionopathy
paresthesias
pembrolizumab
pituitary stalk
pituitary stalk, enlarged
plasmapheresis
pleocytosis of cerebrospinal fluid
polymerase chain reaction, false negative
polyneuropathy, chronic inflammatory demyelinating
precipitating factors
prognosis
progressive multifocal leucoencephalopathy
progressive neurologic disorder
pruritus
pseudoathetosis
ptosis
ptosis, bilateral
radiation therapy, CNS treatment and complications with
rechallenge
recurrent
remote effect of cancer on the nervous system
respiratory failure
review article
rhabdomyolysis
risk factors
Romberg's sign
safety
sarcoidosis
sarcoidosis, CNS
seizure
sensory ganglia
sensory ganglia, abnormal
sensory loss
sensory loss, truncal
seronegative
Sjogren's syndrome
speech disorder
speech, slowed
steroid
steroid therapy, CNS treatment and complications with
systemic illness
temporal lobe, lesion
temporal lobe, lesion, bilateral
trametinib
treatment of neurologic disorder
tumor necrosis factor inhibitor
vasculitides
viral infection, CNS
visual acuity, decreased
visual loss
weakness
weakness, fatiguable
white matter disease
word-finding difficulty
workup
Showing articles 150 to 200 of 865 << Previous Next >>

Intravenous Thrombolysis in Acute Ischemic Stroke Patients Pretreated with Non-Vitamin K Antagonist Oral Anticoagulants
Stroke 48:2031-2033, Tsivgoulis, G. & Safouris, A., 2017

Trial of Tocilizumab in Giant-Cell Arteritis
NEJM 377:317-328,385, Stone, J.H.,et al, 2017

Idarucizumab for Dabigatran Reversal - Full Cohort Analysis
NEJM 377:431-441, Pollack, C.V.,et al, 2017

Alemtuzumab CARE-MS I 5-year follow-up
Neurol 89:1107-1116, Havrdova, E.,et al, 2017

Alemtuzumab CARE-MS II 5-year follow-up
Neurol 89:1117-1126, Coles, A.J.,et al, 2017

Rituximab as Treatment for anti-MuSK myasthenia gravis
Neurol 89:1069-1077, Hehir, M.K.,et al, 2017

Off-Label use of Direct Oral Anticoagulants in Intracerebral Hemorrhage Patients with Prosthetic Valves
Stroke 48:3183-3186, Chaturvedi, S.,et al, 2017

Infliximab for the Treatment of CNS Sarcoidosis
Neurol 89:2092-2100, Gelfand, J.M.,et al, 2017

Should Patients with Ischemic Stroke or Transient Ischemic Attack with Atrial Fibrillation and Microbleeds be Anticoagulated?
Stroke 48:3408-3412, Shoamanesh, A.,et al, 2017

CGRP - The Next Frontier for Migraine
NEJM 377:2190-2191, Hershey, A.D., 2017

Treatment of Cryptogenic Stroke with Active Cancer with a New Oral Anticoagulant
J Stroke Cerebrovasc Dis 26:2976-2980, Nam, K.W.,et al, 2017

Oral Anticoagulants for Prevention of Stroke in Atrial Fibrillation: Systematic Review, Network Meta-Analysis, and Cost Effectiveness Analysis
BMJ 359:J5058, Lopez-Lopez, J.A.,et al, 2017

Clinicopathologic Conference, Paroxysmal Nocturnal Hemoglobinuria
NEJM 377:2581-2590, Case 40-2017, 2017

Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016

Acute Cholecystitis During Treatment with Alemtuzumab in 3 Patients with RRMS
Neurol 87:2380-2381, Pfeuffer, S.,et al, 2016

Trousseaus Syndrome: Cancer-Associated Thrombosis
Jpn J Clin Oncol 46:204-207, Ikushima, S.,et al, 2016

Paraneoplastic Cerebellar Degeneration with Anti-Yo Antibodies - A Review
Ann Clin Trans Neurol 3:655-663, Venkatraman,A. & Opal,P., 2016

Natalizumab-Related PML 2 Weeks after Negative Anti-JCV Antibody Assay
Neurol 86:484-486, Gagne, M.S.,et al, 2016

Early Clinical and Radiological Course, Management, and Outcome of Intracerebral Hemorrhage Related to New Oral Anticoagulants
JAMA Neurol 73:169-177,155, Purrucker, J.C.,et al, 2016

Statin-Associated Autoimmune Myopathy
NEJM 374:664-669, Mammen, A.L., 2016

Safety of Endovascular Thrombectomy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants
Stroke 47:1127-1130, Purrucker, J.C.,et al, 2016

Embolic Stroke, Atrial Fibrillation, and Microbleeds
Stroke 47:904-907, Diener, H-C.,et al, 2016

Diabetic Sensory and Motor Neuropathy
NEJM 374:1455-1464, Vinik, A.I.,et al, 2016

Rituximab Treatment for Autoimmune Limbic Encephalitis in an Institutional Cohort
Neurol 86:1683-1691,1655, Lee, W.J.,et al, 2016

Tocilizumab for Induction and Maintenance of Remission in Giant Cell Arteritis: A Phase 2, Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 387:1921-1927,1882, Villiger, P.M.,et al, 2016

Clinicopathologic Conference, Neurosarcoidosis
NEJM 374:1966-1975, Case 15-2016, 2016

Which Oral Anticoagulation for Atrial Fibrillation?
JAMA 315:2117-2118, The Medical Letter, 2016

Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients
Stroke 47:1555-1561, Shah, A.,et al, 2016

Fulminant Central Nervous System Nocardiosis in a Patient Treated with Alemtuzumab for Relapsing-Remitting Multiple Sclerosis
JAMA Neurol 73:757-759, Penkert, H.,et al, 2016

International Consensus Guidance for Management of Myasthenia Gravis
Neurol 87:419-425, Sanders, D.B.,et al, 2016

Outcomes with Edoxaban Versus Warfarin in Patients with Previous Cerebrovascular Events
Stroke 47:2075-2082, Rost, N.S.,et al, 2016

Primary Prevention of Stroke
JAMA 316:658-659, Steiger, N. & Cifu, A.S., 2016

Stability of International Normalized Ratios in Patients Taking Long-Term Warfarin Therapy
JAMA 316:661-662, Pokorney, S.D.,et al, 2016

Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors
NEJM 375:1131-1141,1185, Connolly, S.J.,et al, 2016

Diagnosis and Treatment of Tourette Syndrome
Neurol 87:e65-e67, Hirschtritt, M.E.,et al, 2016

Superior MRI Outcomes with Alemtuzumab Compared with Subcutaneous Interferon �-1a in MS
Neurol 87:1464-1472, Arnold, D.L.,et al, 2016

Early Start of DOAC after Ischemic Stroke
Neurol 87:1856-1862,1652, Seiffge, D.J.,et al, 2016

Efficacy and Safety of Cholinesterase Inhibitors and Memantine in Cognitive Impairment in Parkinsons Disease, Parkinsons Disease Dementia, and Dementia with Lewy Bodies: Systematic Review with Meta-Analysis and Trial Sequential Analysis
JNNP 86:135-143, Wang, H.F.,et al, 2015

Assessment and Management of Behavioral and Psychological Symptoms of Dementia
BMJ 350:h369, Kales, H.C.,et al, 2015

Risk of Gastrointestinal Bleeding Associated with Oral Anticoagulants: Population Based Retrospective Cohort Study
BMJ 350:h1585, h1679, Chang, H.Y.,et al, 2015

Comparative Risk of Gastrointestinal Bleeding with Dabigatran, Rivaroxaban, and Warfarin: Population Based Cohort Study
BMJ 350:h1857, h1979, Abraham, N.S.,et al, 2015

Newer Agents in the Treatment of Multiple Sclerosis
Neurologist 19:104-117, Pawate, S. & Bagnato F., 2015

Stroke Prevention in Atrial Fibrillation
JAMA 313:1950-1962, Lip, G.Y.H. & Lane, D.A., 2015

Peri-Procedural Management of Patients Taking Oral Anticoagulants
BMJ 351:h2391, Daniels, P.R., 2015

Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: Current Status, Special Situations, and Unmet Needs
Lancet 386:303-310, Verheugt, F.W.A. & Granger, C.B., 2015

Idarucizumab for Dabigatran Reversal
NEJM 373:511-520, Pollack, C.V.,et al, 2015

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 373:1418-1428, Kappos, L.,et al, 2015

CBRNE - Nerve Agents, V-series - Ve, Vg, Vm, Vx
emedicine Feb, Keyes, D.C. & Caneva, D.C., 2015

Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
NEJM 373:2413-2424,2471, Siegal, D.M.,et al, 2015

Endovascular Treatment for Acute Ischemic Stroke in the Setting of Anticoagulation
Stroke 46:3536-3539, Rebello, L.C.,et al, 2015



Showing articles 150 to 200 of 865 << Previous Next >>